<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Sibutramine" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Sibutramine</book-part-id>
      <title-group>
        <title>Sibutramine</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2020</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="ShoSaikoTo" document-type="chapter">Sho Saiko To and Dai Saiko To</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Sildenafil" document-type="chapter">Sildenafil</related-object>
    </book-part-meta>
    <body>
      <sec id="Sibutramine.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Sibutramine.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Sibutramine is a serotonin and norepinephrine reuptake inhibitor which has been used for short- and long-term therapy of obesity, but which was withdrawn from use in the United States in 2010 because of increased risk of cardiovascular events. In large clinical trials, sibutramine therapy was not associated with serum enzyme elevations, and it has only rarely been implicated in cases of clinically apparent, acute liver injury.</p>
        </sec>
        <sec id="Sibutramine.Background">
          <title>Background</title>
          <p>Sibutramine (si bue' tra meen) is a beta-phenylethylamine that inhibits the synaptic reuptake of both serotonin and norepinephrine. Developed initially as an antidepressant, it had little effect on depression, but its use was associated with weight loss that appeared to be due to decreased appetite and reduced caloric intake. Sibutramine was approved for use as therapy of obesity in the United States in 1997 and was widely prescribed until it was withdrawn in 2010 because of studies demonstrating an increased risk of myocardial infarction and stroke with its use. Sibutramine was previously available as capsules of 5, 10 and 15 mg under the trade name Meridia. The recommended dose was 10 mg once daily, with adjustment up to 15 mg daily or down to 5 mg daily based upon clinical effect and tolerance. Common side effects included dry mouth, headache, insomnia, constipation, nausea and increased blood pressure and heart rate. While no longer available commercially, sibutramine has been found as a contaminant in in some weight loss products available over-the-counter or via the internet.</p>
        </sec>
        <sec id="Sibutramine.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Sibutramine has not been linked to an increased rate of serum enzyme elevations during therapy, but the results of serum ALT monitoring have been reported only rarely. Despite its long term availability, only a single case report of acute liver injury attributed to sibutramine has been published. The time to onset was 2 weeks and the pattern of liver enzyme elevation was cholestatic. The liver injury was anicteric and self-limited in course (Case 1). Immunoallergic and autoimmune features were absent. There have been no reports of acute liver failure or chronic liver injury attributed to sibutramine.</p>
        </sec>
        <sec id="Sibutramine.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>The mechanism by which sibutramine might cause liver injury is not known. Sibutramine undergoes extensive hepatic metabolism, primarily by the cytochrome P450 system (CYP 3A4) to its active metabolite which may be further metabolized and conjugated in the liver. Thus, a possible mode of liver injury is production of a toxic intermediate.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="WeightLossAgents" document-type="chapter">Weight Loss Agents</related-object></p>
        </sec>
      </sec>
      <sec id="Sibutramine.CASE_REPORT">
        <title>CASE REPORT</title>
        <sec id="Sibutramine.Case_1_Anicteric_acute_liver">
          <title>Case 1. Anicteric acute liver injury attributed to sibutramine use.(<xref ref-type="bibr" rid="Sibutramine.REF.1">1</xref>)</title>
          <p>A 47 year old obese woman with type 2 diabetes developed fatigue, weakness and pruritus followed by dark urine and jaundice arising 2 weeks after starting sibutramine (10 mg daily). She had no history of liver disease, alcohol abuse or risk factors for viral hepatitis. Her only other medication was insulin. She drank herbal tea. Sibutramine was taken for a total of 20 days and stopped once liver injury was identified. Laboratory testing showed normal serum bilirubin levels, but moderate elevations in ALT (222 U/L), AST (98 U/L) and alkaline phosphatase (763 U/L) (Table). Serological tests for viral hepatitis were negative as were routine autoantibodies. Abdominal ultrasound, computerized tomography and magnetic resonance imaging showed a small gallbladder polyp, but no evidence of liver enlargement or biliary obstruction. A liver biopsy showed a mixed inflammatory infiltrate without fibrosis or cholestasis. Upon stopping the medication, she began to improve clinically and laboratory tests fell rapidly and were normal when tested 8 months later.</p>
          <sec id="Sibutramine.Key_Points">
            <title>Key Points</title>
            <table-wrap id="Sibutramine.Tc" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <tbody>
                  <tr>
                    <th id="hd_b_Sibutramine.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Medication:</th>
                    <td headers="hd_b_Sibutramine.Tc_1_1_1_1" valign="top" align="left" rowspan="1" colspan="1">Sibutramine (10 mg daily)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Sibutramine.Tc_1_1_2_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Pattern:</th>
                    <td headers="hd_b_Sibutramine.Tc_1_1_2_1" valign="top" align="left" rowspan="1" colspan="1">Cholestatic (R=0.8)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Sibutramine.Tc_1_1_3_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Severity:</th>
                    <td headers="hd_b_Sibutramine.Tc_1_1_3_1" valign="top" align="left" rowspan="1" colspan="1">1+ (enzyme elevations without jaundice)</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Sibutramine.Tc_1_1_4_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Latency:</th>
                    <td headers="hd_b_Sibutramine.Tc_1_1_4_1" valign="top" align="left" rowspan="1" colspan="1">2 weeks to symptoms, 3 weeks to jaundice</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Sibutramine.Tc_1_1_5_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Recovery:</th>
                    <td headers="hd_b_Sibutramine.Tc_1_1_5_1" valign="top" align="left" rowspan="1" colspan="1">2-3 months</td>
                  </tr>
                  <tr>
                    <th id="hd_b_Sibutramine.Tc_1_1_6_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Other medications:</th>
                    <td headers="hd_b_Sibutramine.Tc_1_1_6_1" valign="top" align="left" rowspan="1" colspan="1">Insulin, herbal tea</td>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Sibutramine.Laboratory_Values">
            <title>Laboratory Values</title>
            <table-wrap id="Sibutramine.Td" orientation="portrait" position="anchor">
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_Sibutramine.Td_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">Time After<break/>Starting</th>
                    <th id="hd_h_Sibutramine.Td_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">Weeks After<break/>Stopping</th>
                    <th id="hd_h_Sibutramine.Td_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">ALT<break/>(U/L)</th>
                    <th id="hd_h_Sibutramine.Td_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">Alk P<break/>(U/L)</th>
                    <th id="hd_h_Sibutramine.Td_1_1_1_5" valign="top" align="center" scope="col" rowspan="1" colspan="1">GGT<break/>(U/L)</th>
                    <th id="hd_h_Sibutramine.Td_1_1_1_6" valign="top" align="center" scope="col" rowspan="1" colspan="1">Other</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_1" valign="top" align="center" scope="row" rowspan="1" colspan="1">3 weeks</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_2" valign="top" align="center" rowspan="1" colspan="1">0</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">222</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">763</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">925</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">Sibutramine stopped</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_1" valign="top" align="center" scope="row" rowspan="1" colspan="1">9 weeks</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_2" valign="top" align="center" rowspan="1" colspan="1">6 weeks</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">41</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">179</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">228</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_6" valign="top" align="center" rowspan="1" colspan="1">Asymptomatic</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_1" valign="top" align="center" scope="row" rowspan="1" colspan="1">5 months</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_2" valign="top" align="center" rowspan="1" colspan="1">4 months</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">29</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">154</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">60</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_1" valign="top" align="center" scope="row" rowspan="1" colspan="1">7 months</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_2" valign="top" align="center" rowspan="1" colspan="1">6 months</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">70</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">139</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">92</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_1" valign="top" align="center" scope="row" rowspan="1" colspan="1">9 months</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_2" valign="top" align="center" rowspan="1" colspan="1">8 months</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">33</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">75</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">30</td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_1 hd_h_Sibutramine.Td_1_1_1_2" colspan="2" valign="top" align="center" scope="row" rowspan="1">
                      <bold>Normal Values</bold>
                    </td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_3" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;42</bold>
                    </td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_4" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;115</bold>
                    </td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_5" valign="top" align="center" rowspan="1" colspan="1">
                      <bold>&#x0003c;50</bold>
                    </td>
                    <td headers="hd_h_Sibutramine.Td_1_1_1_6" valign="top" align="left" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
          </sec>
          <sec id="Sibutramine.Comment">
            <title>Comment</title>
            <p>The timing of onset of liver test abnormalities, the cholestatic pattern of enzyme elevations and the liver histology were all compatible with drug induced liver injury, and the only apparent candidate was sibutramine. Normalization of the alkaline phosphatase and GGT were delayed, but this is common after cholestatic liver injury. The lack of bilirubin elevation indicates that the injury, while symptomatic, was mild.</p>
          </sec>
        </sec>
      </sec>
      <sec id="Sibutramine.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Sibutramine &#x02013; Meridia&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Weight Loss Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=sibutramine">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Sibutramine.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Sibutramine.Te" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Sibutramine.Te_1_1_1_1" valign="top" align="center" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Sibutramine.Te_1_1_1_2" valign="top" align="center" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Sibutramine.Te_1_1_1_3" valign="top" align="center" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Sibutramine.Te_1_1_1_4" valign="top" align="center" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Sibutramine.Te_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Sibutramine</td>
                <td headers="hd_h_Sibutramine.Te_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135022744">106650-56-0</ext-link>
                </td>
                <td headers="hd_h_Sibutramine.Te_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C17-H26-Cl-N</td>
                <td headers="hd_h_Sibutramine.Te_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135022744" document-id-type="sid" document-type="summary" object-id="135022744" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Sibutramine.CITED_REFERENCE">
        <title>CITED REFERENCE</title>
        <ref-list id="Sibutramine.CITED_REFERENCE.reflist0">
          <ref id="Sibutramine.REF.1">
            <label>1</label>
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chounta</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Tsiodras</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Zouridakis</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Doumas</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Giamarellou</surname>
                  <given-names>H</given-names>
                </name>
              </person-group>
              <article-title>Sibutramine use associated with reversible hepatotoxicity.</article-title>
              <source>Ann Intern Med</source>
              <year>2005</year>
              <volume>143</volume>
              <fpage>763</fpage>
              <lpage>4</lpage>
              <pub-id pub-id-type="pmid">16287809</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec id="Sibutramine.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 06 June 2020</p>
        <ref-list id="Sibutramine.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Sibutramine.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 483-91.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity published in 1999; sibutramine is not mentioned).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Sibutramine.REF.sibley.2018">
            <mixed-citation publication-type="book">Sibley DR, Hazelwood LA, Amara SG. 5-Hydroxytryptamine (serotonin) and dopamine. In, Brunton LL, Hilal-Dandan R, Knollman BC. Goodman &#x00026; Gilman&#x02019;s The pharmacological basis of therapeutics, 13th ed. New York: McGraw-Hill, 2018. p. 225-42.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Sibutramine.REF.luque.1999.968">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Luque</surname>
                  <given-names>CA</given-names>
                </name>
                <name name-style="western">
                  <surname>Rey</surname>
                  <given-names>JA</given-names>
                </name>
              </person-group>
              <article-title>Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.</article-title>
              <source>Ann Pharmacother</source>
              <year>1999</year>
              <volume>33</volume>
              <fpage>968</fpage>
              <lpage>78</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of chemistry, pharmacology, metabolism, clinical efficacy and safety of sibutramine; no mention of hepatitis or ALT elevations in discussion of side effects).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">10492502</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.bray.2000.953">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bray</surname>
                  <given-names>GA</given-names>
                </name>
              </person-group>
              <article-title>A concise review on the therapeutics of obesity.</article-title>
              <source>Nutrition</source>
              <year>2000</year>
              <volume>16</volume>
              <fpage>953</fpage>
              <lpage>60</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Overview of the mechanism of action of antiobesity medications and their clinical efficacy and side effects; no mention of ALT elevations or liver related adverse events).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">11054601</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.haddock.2002.262">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Haddock</surname>
                  <given-names>CK</given-names>
                </name>
                <name name-style="western">
                  <surname>Poston</surname>
                  <given-names>WS</given-names>
                </name>
                <name name-style="western">
                  <surname>Dill</surname>
                  <given-names>PL</given-names>
                </name>
                <name name-style="western">
                  <surname>Foreyt</surname>
                  <given-names>JP</given-names>
                </name>
                <name name-style="western">
                  <surname>Ericsson</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials.</article-title>
              <source>Int J Obes Relat Metab Disord</source>
              <year>2002</year>
              <volume>26</volume>
              <fpage>262</fpage>
              <lpage>73</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Metaanalysis of published studies of anti-obesity medications; sibutramine has been studied in 5 controlled trials published between 1991-98; no discussion of side effects).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">11850760</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.sabuncu.2003.189">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Sabuncu</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Nazligul</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Karaoglanoglu</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Ucar</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Kilic</surname>
                  <given-names>FB</given-names>
                </name>
              </person-group>
              <article-title>The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.</article-title>
              <source>Rom J Gastroenterol</source>
              <year>2003</year>
              <volume>12</volume>
              <fpage>189</fpage>
              <lpage>92</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Trial of 6 month course of sibutramine [n=13] vs orlistat [n=12] in 25 obese patients with nonalcoholic steatohepatitis; both agents were associated with weight loss and improvements in hepatic fat and ALT levels [79 to 32 U/L], but slight increase in Alk P [~175 to ~196 U/L]; no patient stopped therapy because of side effects).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">14502318</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.colman.2005.380">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Colman</surname>
                  <given-names>E.</given-names>
                </name>
              </person-group>
              <article-title>Anorectics on trial: a half century of federal regulation of prescription appetite suppressants.</article-title>
              <source>Ann Intern Med</source>
              <year>2005</year>
              <volume>143</volume>
              <fpage>380</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(History of the approval of medications for obesity from initial agents approved in 1947 to sibutramine in 1997; sibutramine was approved in 1997, but its long term usefulness and safety remain controversial).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">16144896</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.li.2005.532">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Li</surname>
                  <given-names>Z</given-names>
                </name>
                <name name-style="western">
                  <surname>Maglione</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Tu</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Mojica</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Arterburn</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Shugarman</surname>
                  <given-names>LR</given-names>
                </name>
                <name name-style="western">
                  <surname>Hilton</surname>
                  <given-names>L</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Meta-analysis: pharmacologic treatment of obesity.</article-title>
              <source>Ann Intern Med</source>
              <year>2005</year>
              <volume>142</volume>
              <fpage>532</fpage>
              <lpage>46</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of efficacy and safety of medications for obesity; sibutramine effects were evaluated in 29 published studies which showed an overall significant effect on weight loss when combined with lifestyle modification; no serious adverse events and no mention of hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">15809465</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.chounta.2005.763">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chounta</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Tsiodras</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Zouridakis</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Doumas</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Giamarellou</surname>
                  <given-names>H</given-names>
                </name>
              </person-group>
              <article-title>Sibutramine use associated with reversible hepatotoxicity.</article-title>
              <source>Ann Intern Med</source>
              <year>2005</year>
              <volume>143</volume>
              <fpage>763</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(47 year old woman developed fatigue and pruritus 2 weeks after starting a 20 day course of sibutramine [bilirubin normal, ALT 222 U/L, Alk P 763 U/L], resolving 6-8 months after stopping: Case 1).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">16287809</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.bray.2005.89">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Bray</surname>
                  <given-names>GA</given-names>
                </name>
              </person-group>
              <article-title>Drug Insight: appetite suppressants.</article-title>
              <source>Nat Clin Pract Gastroenterol Hepatol</source>
              <year>2005</year>
              <volume>2</volume>
              <fpage>89</fpage>
              <lpage>95</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the mechanism of action and clinical efficacy of drugs that suppress appetite including sympathomimetic agents [amphetamine, phentermine, sibutramine], serotonin reuptake inhibitors [bupropion, fenfluramine, fluoxetine], GABAergic agents [topiramate, zonisamide], cannabinoid antagonists [rimonabant] and various peptides [leptin, neuropeptide Y, melanocortin-4]; no discussion of hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">16265126</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.ioannidesdemos.2006.277">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ioannides-Demos</surname>
                  <given-names>LL</given-names>
                </name>
                <name name-style="western">
                  <surname>Proietto</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Tonkin</surname>
                  <given-names>AM</given-names>
                </name>
                <name name-style="western">
                  <surname>McNeil</surname>
                  <given-names>JJ</given-names>
                </name>
              </person-group>
              <article-title>Safety of drug therapies used for weight loss and treatment of obesity.</article-title>
              <source>Drug Saf</source>
              <year>2006</year>
              <volume>29</volume>
              <fpage>277</fpage>
              <lpage>302</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of safety of drug therapy of obesity; the only mention of liver adverse events was &#x0201c;a case of reversible hepatotoxicity associated with sibutramine&#x0201d;).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">16569079</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.james.2010.905">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>James</surname>
                  <given-names>WP</given-names>
                </name>
                <name name-style="western">
                  <surname>Caterson</surname>
                  <given-names>ID</given-names>
                </name>
                <name name-style="western">
                  <surname>Coutinho</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Finer</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Van Gaal</surname>
                  <given-names>LF</given-names>
                </name>
                <name name-style="western">
                  <surname>Maggioni</surname>
                  <given-names>AP</given-names>
                </name>
                <name name-style="western">
                  <surname>Torp-Pedersen</surname>
                  <given-names>C</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.</article-title>
              <source>N Engl J Med</source>
              <year>2010</year>
              <volume>363</volume>
              <fpage>905</fpage>
              <lpage>17</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Controlled trial of sibutramine vs placebo for an average of 3.4 years in 10,744 overweight or obese subjects with preexisting cardiovascular conditions, found increases in pulse rate, blood pressure, and nonfatal myocardial infarction and stokes; no mention of ALT levels or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">20818901</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF14">
            <element-citation publication-type="journal">
              <article-title>Sibutramine (Meridia) withdrawn.</article-title>
              <source>Med Lett Drugs Ther</source>
              <year>2010</year>
              <volume>52</volume>
              <issue>1350</issue>
              <fpage>88</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Announcement that sibutramine was withdrawn from the market because of concerns over cardiovascular safety in the US, Canada, Europe and Australia, but remains available in other countries).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21045763</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.van_hunsel.2011.a3695">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>van Hunsel</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>van Grootheest</surname>
                  <given-names>K.</given-names>
                </name>
              </person-group>
              <comment>[Adverse drug reactions of a slimming product contaminated with sibutramine]</comment>
              <source>Ned Tijdschr Geneeskd</source>
              <year>2011</year>
              <volume>155</volume>
              <fpage>A3695</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Two reports of adverse events due to "Green Coffee 800", an unregistered weight loss agent that was found to be contaminated with sibutramine; one patient had serum ALT elevations).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22027464</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.ozdemir.2013.101">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ozdemir</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Sahin</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Kapucu</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Celbis</surname>
                  <given-names>O</given-names>
                </name>
                <name name-style="western">
                  <surname>Karakoc</surname>
                  <given-names>Y</given-names>
                </name>
                <name name-style="western">
                  <surname>Erdogan</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Onal</surname>
                  <given-names>Y</given-names>
                </name>
              </person-group>
              <article-title>How safe is the use of herbal weight-loss products sold over the Internet?</article-title>
              <source>Hum Exp Toxicol</source>
              <year>2013</year>
              <volume>32</volume>
              <fpage>101</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Testing of 9 weight loss products sold over the Internet found that all 9 had undeclared ingredients, 3 having sibutramine).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22354083</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.kang.2012.13">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Kang</surname>
                  <given-names>JG</given-names>
                </name>
                <name name-style="western">
                  <surname>Park</surname>
                  <given-names>CY</given-names>
                </name>
              </person-group>
              <article-title>Anti-obesity drugs: a review about their effects and safety.</article-title>
              <source>Diabetes Metab J</source>
              <year>2012</year>
              <volume>36</volume>
              <fpage>13</fpage>
              <lpage>25</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Review of the safety and efficacy of current and potentially future medications for obesity; mentions that the five year cardiovascular outcomes study of sibutramine [James 2010] demonstrated a significant increase in pulse, blood pressure, and risk of nonfatal myocardial infarction and stroke which led to its withdrawal in October 2010).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">22363917</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.reeuwijk.2014.1783">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Reeuwijk</surname>
                  <given-names>NM</given-names>
                </name>
                <name name-style="western">
                  <surname>Venhuis</surname>
                  <given-names>BJ</given-names>
                </name>
                <name name-style="western">
                  <surname>de Kaste</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Hoogenboom</surname>
                  <given-names>RL</given-names>
                </name>
                <name name-style="western">
                  <surname>Rietjens</surname>
                  <given-names>IM</given-names>
                </name>
                <name name-style="western">
                  <surname>Martena</surname>
                  <given-names>MJ</given-names>
                </name>
              </person-group>
              <article-title>Active pharmaceutical ingredients detected in herbal food supplements for weight loss sampled on the Dutch market.</article-title>
              <source>Food Addit Contam Part A Chem Anal Control Expo Risk Assess</source>
              <year>2014</year>
              <volume>31</volume>
              <fpage>1783</fpage>
              <lpage>93</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Sampling of 50 herbal weight loss product by the Netherlands Food and Consumer Product Safety Authority found pharmaceutically active adulterants not listed on the product label in in 24, most commonly sibutramine [n=17] but also rimonabant, sildenafil and phenolphthalein often in pharmacologically significant amounts).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25247833</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.ching.2018.172">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ching</surname>
                  <given-names>CK</given-names>
                </name>
                <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>SPL</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>HHC</given-names>
                </name>
                <name name-style="western">
                  <surname>Lam</surname>
                  <given-names>YH</given-names>
                </name>
                <name name-style="western">
                  <surname>Ng</surname>
                  <given-names>SW</given-names>
                </name>
                <name name-style="western">
                  <surname>Chen</surname>
                  <given-names>ML</given-names>
                </name>
                <name name-style="western">
                  <surname>Tang</surname>
                  <given-names>MHY</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Adulteration of proprietary Chinese medicines and health products with undeclared drugs: experience of a tertiary toxicology laboratory in Hong Kong.</article-title>
              <source>Br J Clin Pharmacol</source>
              <year>2018</year>
              <volume>84</volume>
              <fpage>172</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Over a 10 year period 487 adulterated proprietary Chinese medical products were identified by a toxicology laboratory in Hong Kong, the contaminants being mostly NSAIDs, anorectics, corticosteroids and diuretics, the single most common contaminant being sibutramine [present in 155 products: 32%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">28965348</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.dedov.2018.335">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Dedov</surname>
                  <given-names>II</given-names>
                </name>
                <name name-style="western">
                  <surname>Melnichenko</surname>
                  <given-names>GA</given-names>
                </name>
                <name name-style="western">
                  <surname>Troshina</surname>
                  <given-names>EA</given-names>
                </name>
                <name name-style="western">
                  <surname>Mazurina</surname>
                  <given-names>NV</given-names>
                </name>
                <name name-style="western">
                  <surname>Galieva</surname>
                  <given-names>MO</given-names>
                </name>
              </person-group>
              <article-title>Body weight reduction associated with the sibutramine treatment: overall results of the PRIMAVERA primary health care trial.</article-title>
              <source>Obes Facts</source>
              <year>2018</year>
              <volume>11</volume>
              <fpage>335</fpage>
              <lpage>43</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 98,774 patients enrolled in a sibutramine treatment program in Russia, therapy with sibutramine resulted in weight loss in most subjects and there were no serious adverse events; no mention of ALT levels or hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">30089303</pub-id>
            </element-citation>
          </ref>
          <ref id="Sibutramine.REF.biesterbos.2019.1273">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Biesterbos</surname>
                  <given-names>JWH</given-names>
                </name>
                <name name-style="western">
                  <surname>Sijm</surname>
                  <given-names>DTHM</given-names>
                </name>
                <name name-style="western">
                  <surname>van Dam</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Mol</surname>
                  <given-names>HGJ</given-names>
                </name>
              </person-group>
              <article-title>A health risk for consumers: the presence of adulterated food supplements in the Netherlands.</article-title>
              <source>Food Addit Contam Part A Chem Anal Control Expo Risk Assess</source>
              <year>2019</year>
              <volume>36</volume>
              <fpage>1273</fpage>
              <lpage>88</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Analysis of 416 commercial dietary supplements by the Netherlands Food and Consumer Product Safety Authority between 2013 and 2018 identified 264 [64%] as having an adulterant, the most common being caffeine and synephrine, sildenafil, icariin, higenamine and sibutramine [n=22: 5.2%]).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">31294678</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Sibutramine.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=Sibutramine+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Sibutramine: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Sibutramine">Trials on Sibutramine: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
